Meropenem and piperacillin/tazobactam prescribing in critically ill patients: Does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?

Critical Care

Volumn 17, Issue 3, 2013, Pages

  Carlier, Mieke ^a   Carrette, Sofie ^a   Roberts, Jason A ^b,c   Stove, Veronique ^d   Verstraete, Alain ^a   Hoste, Eric ^a   Depuydt, Pieter ^a   Decruyenaere, Johan ^a   Lipman, Jeffrey ^b,c   Wallis, Steven C ^b,c   De Waele, Jan J ^a  

^a GHENT UNIVERSITY   (Belgium)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

lactam antibiotics; hyperfiltration; kidney function; pharmacodynamics; pharmacokinetics; therapeutic drug monitoring

Indexed keywords

MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; CREATININE; PENICILLANIC ACID; PIPERACILLIN; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION; THIENAMYCIN DERIVATIVE;

AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; BLOOD SAMPLING; COHORT ANALYSIS; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG TREATMENT FAILURE; DRUG URINE LEVEL; GLOMERULUS FILTRATION RATE; HUMAN; INTENSIVE CARE UNIT; KIDNEY CLEARANCE; LIMIT OF QUANTITATION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MEDICAL INFORMATION SYSTEM; MINIMUM INHIBITORY CONCENTRATION; OBSERVATIONAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; UNIVERSITY HOSPITAL; URINALYSIS; ADULT; AGED; ANALOGS AND DERIVATIVES; CRITICAL ILLNESS; DRUG DELIVERY SYSTEM; DRUG EFFECTS; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; MALE; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; PHYSIOLOGY; PROCEDURES;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CREATININE; CRITICAL ILLNESS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PENICILLANIC ACID; PIPERACILLIN; PROSPECTIVE STUDIES; THIENAMYCINS;

EID: 84877003713     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc12705     Document Type: Article

References (36)

1. Vincent J-L, Rello J, Marshall J, Silva E, Anzueto A, Martin CD, Moreno R, Lipman J, Gomersall C, Sakr Y, Reinhart K, EPICII Group of Investigators International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009, 302:2323-2329. 10.1001/jama.2009.1754, 19952319, EPICII Group of Investigators.
2. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M, Early Goal-Directed Therapy Collaborative Group Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001, 345:1368-1377. 10.1056/NEJMoa010307, 11794169, Early Goal-Directed Therapy Collaborative Group.
3. Leibovici L, Shraga I, Drucker M, Konigsberger H, Samra Z, Pitlik SD. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998, 244:379-386. 10.1046/j.1365-2796.1998.00379.x, 9845853.
4. Roberts JA, Ulldemolins M, Roberts MS, McWhinney B, Ungerer J, Paterson DL, Lipman J. Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents 2010, 36:332-339. 10.1016/j.ijantimicag.2010.06.008, 20685085.
5. Taccone FS, Laterre P-F, Dugernier T, Spapen H, Delattre I, Wittebole X, De Backer D, Layeux B, Wallemacq P, Vincent JL, Jacobs F. Insufficient beta-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 2010, 14:R126. 10.1186/cc9091, 2945087, 20594297.
6. Navas D, Caillon J, Batard E, Le Conte P, Kergueris MF, Moreau P, Potel G. Trough serum concentrations of beta-lactam antibiotics in cancer patients: inappropriateness of conventional schedules to pharmacokinetic/pharmacodynamic properties of beta-lactams. Int J Antimicrob Agents 2006, 27:102-107. 10.1016/j.ijantimicag.2005.09.016, 16414248.
7. Roberts DM, Roberts JA, Roberts MS, Liu X, Nair P, Cole L, Lipman J, Bellomo R. Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: A multicentre pharmacokinetic study*. Crit Care Med 2012, 40:1523-1528. 10.1097/CCM.0b013e318241e553, 22511133.
8. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009, 37:840-851. 10.1097/CCM.0b013e3181961bff, 19237886.
9. Udy AA, Putt MT, Boots RJ, Lipman J. ARC - Augmented Renal Clearance. Curr Pharm Biotechnol 2011, 12:2020-2029. 10.2174/138920111798808446, 21554215.
10. Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance implications for antibacterial dosing in the critically ill. Clin Pharmacokinet 2010, 49:1-16. 10.2165/11318140-000000000-00000, 20000886.
11. Fuster-Lluch O, Geronimo-Pardo M, Peyro-Garcia R, Lizan-Garcia M. Glomerular hyperfiltration and albuminuria in critically ill patients. Anaesth Intensive Care 2008, 36:674-680.
12. Udy A, Boots R, Senthuran S, Stuart J, Deans R, Lassig-Smith M, Lipman J. Augmented creatinine clearance in traumatic brain injury. Anesth Analg 2010, 111:1505-1510. 10.1213/ANE.0b013e3181f7107d, 21048095.
13. Conil JM, Georges B, Lavit M, Seguin T, Tack I, Samil K, Chabanon G, Houin G, Saivin S. Pharmacokinetics of ceftazidime and cefepime in burn patients: The importance of age and creatinine clearance. Int J Clin Pharmacol Ther 2007, 45:529-538. 10.5414/CPP45529, 17966838.
14. Udy AA, Varghese JM, Altukroni M, Briscoe S, McWhinney BC, Ungerer JP, Lipman J, Roberts JA. Subtherapeutic initial beta-lactam concentrations in select critically ill patients association between augmented renal clearance and low trough drug concentrations. Chest 2012, 142:30-39. 10.1378/chest.11-1671, 22194591.
15. McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 2008, 31:345-351. 10.1016/j.ijantimicag.2007.12.009, 18313273.
16. McWhinney BC, Wallis SC, Hillister T, Roberts JA, Lipman J, Ungerer JPJ. Analysis of 12 beta-lactam antibiotics in human plasma by HPLC with ultraviolet detection. J Chromatogr B 2010, 878:2039-2043.
17. Antimicrobial wild type distributions of microorganisms, http://mic.eucast.org/Eucast2/SearchController/search.jsp?action=init
18. Zeitlinger MA, Erovic BM, Sauermann R, Georgopoulos A, Muller M, Joukhadar C. Plasma concentrations might lead to overestimation of target site activity of piperacillin in patients with sepsis. J Antimicrob Chemother 2005, 56:703-708. 10.1093/jac/dki284, 16120628.
19. Kitzes-Cohen R, Farin D, Piva G, De Myttenaere-Bursztein SA. Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients. Int J Antimicrob Agents 2002, 19:105-110. 10.1016/S0924-8579(01)00474-5, 11850162.
20. Roos JF, Lipman J, Kirkpatrick CMJ. Population pharmacokinetics and pharmacodynamics of cefpirome in critically ill patients against Gram-negative bacteria. Intensive Care Med 2007, 33:781-788. 10.1007/s00134-007-0573-7, 17342515.
21. Angus BJ, Smith MD, Suputtamongkol Y, Mattie H, Walsh AL, Wuthiekanun V, Chaowagul W, White NJ. Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis. Br J Clin Pharmacol 2000, 49:445-452. 2014958, 10792202.
22. Li C, Kuti JL, Nightingale CH, Mansfield DL, Dana A, Nicolau DP. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. J Antimicrob Chemother 2005, 56:388-395. 10.1093/jac/dki243, 16002420.
23. Young RJ, Lipman J, Gin T, Gomersall CD, Joynt GM, Oh TE. Intermittent bolus dosing of ceftazidime in critically ill patients. J Antimicrob Chemother 1997, 40:269-273. 10.1093/jac/40.2.269, 9301994.
24. Tam VH, McKinnon PS, Akins RL, Drusano GL, Rybak MJ. Pharmacokinetics and pharmacodynamics of cefepime in patients with various degrees of renal function. Antimicrob Agents Chemother 2003, 47:1853-1861. 10.1128/AAC.47.6.1853-1861.2003, 155813, 12760858.
25. Lipman J, Wallis SC, Rickard C. Low plasma cefepime levels in critically ill septic patients: Pharmacokinetic modeling indicates improved troughs with revised dosing. Antimicrob Agents Chemother 1999, 43:2559-2561. 89521, 10508045.
26. Lipman J, Wallis SC, Rickard CM, Fraenkel D. Low cefpirome levels during twice daily dosing in critically ill septic patients: pharmacokinetic modelling calls for more frequent dosing. Intensive Care Med 2001, 27:363-370. 10.1007/s001340000741, 11396280.
27. Turnidge JD. The Pharmacodynamics of β-Lactams. Clin Infect Dis 1998, 27:10-22. 10.1086/514622, 9675443.
28. McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 2008, 31:345-351. 10.1016/j.ijantimicag.2007.12.009, 18313273.
29. Vogelman B, Craig WA. Kinetics of antimicrobial activity. J Pediatr 1986, 108:835-840. 10.1016/S0022-3476(86)80754-5, 3701535.
30. Li C, Du X, Kuti JL, Nicolau DP. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother 2007, 51:1725-1730. 10.1128/AAC.00294-06, 1855547, 17307978.
31. Tröger U, Drust A, Martens-Lobenhoffer J, Tanev I, Braun-Dullaeus RC, Bode-Böger SM. Decreased meropenem levels in Intensive Care Unit patients with augmented renal clearance: benefit of therapeutic drug monitoring. Int J Antimicrob Agents 2012, 40:370-372. 10.1016/j.ijantimicag.2012.05.010, 22795654.
32. Udy AA, Putt MT, Shanmugathasan S, Roberts JA, Lipman J. Augmented renal clearance in the Intensive Care Unit: an illustrative case series. Int J Antimicrob Agents 2010, 35:606-608. 10.1016/j.ijantimicag.2010.02.013, 20307958.
33. Baptista JP, Sousa E, Martins PJ, Pimentel JM. Augmented renal clearance in septic patients and implications for vancomycin optimisation. Int J Antimicrob Agents 2012, 39:420-423. 10.1016/j.ijantimicag.2011.12.011, 22386742.
34. Martin JH, Fay MF, Udy A, Roberts J, Kirkpatrick C, Ungerer J, Lipman J. Pitfalls of using estimations of glomerular filtration rate in an intensive care population. Intern Med J 2011, 41:537-543. 10.1111/j.1445-5994.2009.02160.x, 21762334.
35. Baptista JP, Udy AA, Sousa E, Pimentel J, Wang L, Roberts JA, Lipman J. A comparison of estimates of glomerular filtration in critically ill patients with augmented renal clearance. Crit Care 2011, 15:R139. 10.1186/cc10262, 3219011, 21651804.
36. Roberts JA, Hope WW, Lipman J. Therapeutic drug monitoring of beta-lactams for critically ill patients: unwarranted or essential?. Int J Antimicrob Agents 2010, 35:419-420. 10.1016/j.ijantimicag.2010.01.022, 20189777.